All In Biotech

NDA 217729 · Pf Prism Cv

Bosulif

Bosutinib Monohydrate · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 26, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

67

6 Phase 3, 5 recruiting

FAERS reports

8,981

5,051 serious, 799 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 10, 2026.

BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )

Mechanism: Bosutinib is a TKI. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 26, 2023 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
  • BOSULIF · BOSUTINIB MONOHYDRATE EQ 100MG BASE · CAPSULE, ORAL · Prescription
  • BOSULIF · BOSUTINIB MONOHYDRATE EQ 50MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bosutinib" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,078
  • nausea1,020
  • fatigue728
  • vomiting544
  • death538
  • rash492
  • pleural effusion458
  • neoplasm progression373
  • dyspnoea364
  • headache339
  • off label use330
  • drug intolerance318

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20093
20107
20117
201260
2013270
2014398
2015540
2016504
2017575
2018697
2019966
2020865
2021817
2022851
2023993
2024737
2025484
2026207

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bosulif (Bosutinib)

2024 spending

$235M

Beneficiaries

1,981

15,541 claims

Per beneficiary

$118,784

$357.00 per unit

View as table
YearSpending
2020$123,423,995
2021$147,656,080
2022$170,022,055
2023$199,137,491
2024$235,311,823

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.